EGFR and glioblastoma: Conversely, a small cohort study [126] evaluating the efficacy of TKI osimertinib plus bevacizumab and standard therapy in glioblastoma patients with EGFR amplification and EGFRvIII mutation showed marginal effectiveness in PFS and OS; however, a small subset of patients actually developed meaningful benefit, which could prompt further studies on the specific characteristics that made them more responsive to therapy.